Vifor Pharma, Cara Therapeutics to commercialise kidney disease drug Korsuva in US

This article was originally published here

In May 2018, Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) entered into an initial agreement to develop and commercialise Korsuva to treat CKD-aP in haemodialysis

The post Vifor Pharma, Cara Therapeutics to commercialise kidney disease drug Korsuva in US appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply